CT
UBIO

CMT Trading’s Proshares UltraPro NASDAQ Biotechnology UBIO Stock Holding History

CMT Trading’s Portfolio UBIO Stock Details UBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-3,496
Closed -$250K – 38
2015
Q4 		$250K Buy
+3,496
New +$185K 1.02% 12

Other funds holding UBIO

VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CG
Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

CMT Trading's UBIO Position: Q1 2016 in Review

CMT Trading sold out of Proshares UltraPro NASDAQ Biotechnology (UBIO) in Q1 2016, closing a stake of 3,496 shares — an estimated $250K sold.

CMT Trading first reported a position in UBIO in Q4 2015 and held it in 1 quarter. The position peaked at $250K in Q4 2015. 7 funds tracked by Wall St. Rank hold UBIO as of Q1 2016.

  • CMT Trading reported no remaining Proshares UltraPro NASDAQ Biotechnology position as of Q1 2016 after selling out during the quarter.
  • CMT Trading sold 3,496 Proshares UltraPro NASDAQ Biotechnology shares in Q1 2016, an estimated $250K.
  • CMT Trading first reported a position in Proshares UltraPro NASDAQ Biotechnology in Q4 2015 and held it in 1 quarter.
  • CMT Trading's Proshares UltraPro NASDAQ Biotechnology position peaked at $250K in Q4 2015.
  • 7 funds tracked by Wall St. Rank held Proshares UltraPro NASDAQ Biotechnology as of Q1 2016.

Based on CMT Trading's 13F filing for Q1 2016, filed 16 May 2016.